191 related articles for article (PubMed ID: 9166292)
41. Effect of Nma on growth inhibition by TGF-betaa in human gastric carcinoma cell lines.
Sasaki T; Sasahira T; Shimura H; Ikeda S; Kuniyasu H
Oncol Rep; 2004 Jun; 11(6):1219-23. PubMed ID: 15138559
[TBL] [Abstract][Full Text] [Related]
42. Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.
Lücke CD; Philpott A; Metcalfe JC; Thompson AM; Hughes-Davies L; Kemp PR; Hesketh R
Cancer Res; 2001 Jan; 61(2):482-5. PubMed ID: 11212236
[TBL] [Abstract][Full Text] [Related]
43. Transforming growth factor-beta receptors in human cancer cell lines: analysis of transcript, protein and proliferation.
Jakowlew SB; Moody TW; Mariano JM
Anticancer Res; 1997; 17(3C):1849-60. PubMed ID: 9216635
[TBL] [Abstract][Full Text] [Related]
44. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
Deng X; Bellis S; Yan Z; Friedman E
Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
[TBL] [Abstract][Full Text] [Related]
45. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3).
Chen A; Davis BH; Sitrin MD; Brasitus TA; Bissonnette M
Am J Physiol Gastrointest Liver Physiol; 2002 Oct; 283(4):G864-74. PubMed ID: 12223346
[TBL] [Abstract][Full Text] [Related]
46. Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors.
Yamada SD; Baldwin RL; Karlan BY
Gynecol Oncol; 1999 Oct; 75(1):72-7. PubMed ID: 10502429
[TBL] [Abstract][Full Text] [Related]
47. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
[TBL] [Abstract][Full Text] [Related]
48. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Goggins M; Shekher M; Turnacioglu K; Yeo CJ; Hruban RH; Kern SE
Cancer Res; 1998 Dec; 58(23):5329-32. PubMed ID: 9850059
[TBL] [Abstract][Full Text] [Related]
49. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Lee BI; Park SH; Kim JW; Sausville EA; Kim HT; Nakanishi O; Trepel JB; Kim SJ
Cancer Res; 2001 Feb; 61(3):931-4. PubMed ID: 11221885
[TBL] [Abstract][Full Text] [Related]
50. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells.
Grau AM; Zhang L; Wang W; Ruan S; Evans DB; Abbruzzese JL; Zhang W; Chiao PJ
Cancer Res; 1997 Sep; 57(18):3929-34. PubMed ID: 9307274
[TBL] [Abstract][Full Text] [Related]
51. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
52. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
Amendt C; Schirmacher P; Weber H; Blessing M
Oncogene; 1998 Jul; 17(1):25-34. PubMed ID: 9671311
[TBL] [Abstract][Full Text] [Related]
53. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Muro-Cacho CA; Rosario-Ortiz K; Livingston S; Muñoz-Antonia T
Clin Cancer Res; 2001 Jun; 7(6):1618-26. PubMed ID: 11410498
[TBL] [Abstract][Full Text] [Related]
54. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.
Kiss A; Wang NJ; Xie JP; Thorgeirsson SS
Clin Cancer Res; 1997 Jul; 3(7):1059-66. PubMed ID: 9815784
[TBL] [Abstract][Full Text] [Related]
55. Generation of active TGF-beta by prostatic cell cocultures using novel basal and luminal prostatic epithelial cell lines.
Salm SN; Koikawa Y; Ogilvie V; Tsujimura A; Coetzee S; Moscatelli D; Moore E; Lepor H; Shapiro E; Sun TT; Wilson EL
J Cell Physiol; 2000 Jul; 184(1):70-9. PubMed ID: 10825235
[TBL] [Abstract][Full Text] [Related]
56. Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein.
Lazzereschi D; Ranieri A; Mincione G; Taccogna S; Nardi F; Colletta G
Cancer Res; 1997 May; 57(10):2071-6. PubMed ID: 9158007
[TBL] [Abstract][Full Text] [Related]
57. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.
Obiri NI; Hillman GG; Haas GP; Sud S; Puri RK
J Clin Invest; 1993 Jan; 91(1):88-93. PubMed ID: 8423237
[TBL] [Abstract][Full Text] [Related]
58. Effects of TNF-alpha and retinoic acid on the proliferation of the clear cell and chromophilic types of human renal cell carcinoma in vitro.
Gerharz CD; Ramp U; Reinecke P; Ressler U; Dienst M; Marx N; Friebe U; Engers R; Pollow K; Gabbert HE
Anticancer Res; 1996; 16(4A):1633-41. PubMed ID: 8712681
[TBL] [Abstract][Full Text] [Related]
59. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.
Kim IY; Lee DH; Lee DK; Kim BC; Kim HT; Leach FS; Linehan WM; Morton RA; Kim SJ
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6046-51. PubMed ID: 14676131
[TBL] [Abstract][Full Text] [Related]
60. IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells.
Rosendahl AH; Forsberg G
Kidney Int; 2006 Nov; 70(9):1584-90. PubMed ID: 16969385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
